<DOC>
	<DOCNO>NCT01365624</DOCNO>
	<brief_summary>This study open-label , single-dose design . All subject receive single dose 30 mg intranasal ketorolac . Blood sample determination ketorolac plasma level obtain pre-dose specified time point 24 hour post-dose . The primary objective trial compare pharmacokinetics intranasal ketorolac elderly nonelderly adult subject . The secondary objective evaluate safety profile intranasal ketorolac elderly subject .</brief_summary>
	<brief_title>Safety Pharmacokinetics Study Intranasal Ketorolac Elderly Nonelderly Adult Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Ketorolac</mesh_term>
	<mesh_term>Ketorolac Tromethamine</mesh_term>
	<criteria>The elderly population consist male female volunteer age &gt; = 65 year The nonelderly adult population consist male female volunteer age &lt; 65 year Generally good health opinion Investigator , determine prestudy physical examination clinically significant abnormality age , vital sign within normal range outside normal range deem clinically significant age opinion Investigator , clinically significant electrocardiogram ( ECG ) abnormalities age Bilaterally patent nasal airways screen assess Investigator Body mass index ( BMI ) 1530 kg/m2 Female subject childbearing potential must consent use medically acceptable method contraception ( oral implant contraceptive hormone , condom diaphragm spermicidal agent , intrauterine device , surgical sterilization ) throughout study period Ability provide write informed consent Prestudy clinical laboratory finding within normal range outside normal range deem clinically significant age opinion Investigator Allergy sensitivity ketorolac formulation ingredient History coexist nasal polyp , NSAID sensitivity , asthma Allergic reaction aspirin NSAIDs Current upper respiratory tract infection respiratory tract condition could interfere absorption nasal spray assessment AEs Use prescribe overthecounter ( OTC ) drug 72 h prior entry study exception occasional acetaminophen 24 h prior entry Suspicion rhinitis medicamentosa ( chronic daily use topical decongestant ) Use monoamine oxidase ( MAO ) inhibitor 14 day prior study entry Positive serum test human immunodeficiency virus ( HIV ) hepatitis B C Positive alcohol breath test screen entry study Positive urine screen nonprescribed drug abuse screen entry study History cocaine use Blood donation within 30 day begin study participation Active peptic ulcer disease history peptic ulcer disease gastrointestinal bleeding Serum creatinine &gt; 2.0 mg/dL Current tobacco use past history smoking within 5 year study entry Any clinically significant medical problem , opinion Investigator would interfere study participation Participation within 30 day study entry within 5 time halflife , whichever longer , another investigational drug study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>